Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. That said, here is one unprofitable company investing heavily to secure market share and two best left off your radar.
Two Stocks to Sell:
Simply Good Foods (SMPL)
Trailing 12-Month GAAP Operating Margin: -9.1%
Best known for its Atkins brand that was inspired by the popular diet of the same name, Simply Good Foods (NASDAQ: SMPL) is a packaged food company whose offerings help customers achieve their healthy eating or weight loss goals.
Why Do We Pass on SMPL?
- Muted 6% annual revenue growth over the last three years shows its demand lagged behind its consumer staples peers
- Projected sales decline of 4.9% for the next 12 months points to a tough demand environment ahead
- Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 24.4 percentage points
Simply Good Foods’s stock price of $13.50 implies a valuation ratio of 7.9x forward P/E. To fully understand why you should be careful with SMPL, check out our full research report (it’s free).
10x Genomics (TXG)
Trailing 12-Month GAAP Operating Margin: -9.5%
Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ: TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.
Why Do We Steer Clear of TXG?
- Muted 1.9% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Revenue base of $642.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Negative returns on capital show that some of its growth strategies have backfired
10x Genomics is trading at $22.42 per share, or 4.6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than TXG.
One Stock to Buy:
Samsara (IOT)
Trailing 12-Month GAAP Operating Margin: -3.2%
From sensors on vehicles to AI-powered cameras that help prevent accidents, Samsara (NYSE: IOT) is a cloud-based Internet of Things platform that helps businesses improve the safety, efficiency, and sustainability of their physical operations.
Why Is IOT a Top Pick?
- ARR growth averaged 29.8% over the last year, showing customers are willing to take multi-year bets on its software
- Projected revenue growth of 21.8% for the next 12 months suggests its momentum from the last two years will persist
- Software platform has product-market fit given the rapid recovery of its customer acquisition costs
At $29.67 per share, Samsara trades at 8.9x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
